Predictive Oncology Inc. (NASDAQ: POAI) Finalizes Acquisition Deal Expected to Revolutionize Role of AI-Driven Predictive Models
POAI completes acquisition designed to accelerate commercialization of proprietary AI-driven drug discovery, development Strategic move allows for one-of-a-kind, end-to-end ‘discovery machine’ that can rapidly generate potential therapeutic candidates Company to offer new capability to pharmaceutical company customers in revenue-generating projects later this year Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, has completed its acquisition of Quantitative Medicine (“QM”) (http://ibn.fm/vqmwL). POAI signed a letter of intent to acquire QM, a biomedical analytics and computational biology company, in January (http://ibn.fm/4iRTV). The strategic move should accelerate the commercialization of Predictive Oncology’s proprietary AI-driven drug discovery and…